Status:
COMPLETED
Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-78 years
Phase:
PHASE3
Brief Summary
A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin/peroxisome proliferator-activated recep...
Eligibility Criteria
Inclusion
- Patient has type 2 diabetes mellitus
- Patient is inadequately controlled while taking two oral antidiabetic medications
Exclusion
- Patient has a history of type 1 diabetes mellitus or history of ketoacidosis
- Patient required insulin therapy within the prior 3 months
- Patient has been taking Byetta (R) (exenatide) within the prior 3 months
Key Trial Info
Start Date :
June 12 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 11 2008
Estimated Enrollment :
262 Patients enrolled
Trial Details
Trial ID
NCT00350779
Start Date
June 12 2006
End Date
June 11 2008
Last Update
May 12 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.